Biofrontera Inc. Warrants (BFRIW)

Biofrontera Q2 Revenue Jumps 15%

Biofrontera reported a 15% revenue increase in Q2 2025, with record Ameluz sales and strategic shifts towards a royalty model. The company is advancing clinical trials for label expansions in actinic keratosis and basal cell carcinoma treatments.

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Biofrontera reported Q2 2025 revenues of $9.0 million, a 15% increase from the previous year. The company restructured its relationship with Biofrontera AG, acquiring US intellectual property and securing $11 million in funding. Despite increased legal expenses, the company saw improvements in sales effectiveness and is progressing with clinical trials for Ameluz®.